Gene Therapy and Genome Editing for Inherited Metabolic and Hematologic Disorders
This community develops clinical treatments for genetic diseases by correcting defective genes or replacing missing proteins, primarily using viral vectors and gene-editing tools.
The research focuses on delivering functional genes to patients with conditions such as Pompe disease, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and sickle cell disease. Key methods include adeno-associated virus (AAV) vectors for in vivo delivery and CRISPR-Cas9 or prime editing for precise genomic modifications. A significant portion of the work addresses the challenges of immune responses to viral vectors and the development of hematopoietic stem cell-based therapies. The literature also covers the application of these techniques to cerebral adrenoleukodystrophy and hemophilia, with a strong emphasis on clinical trial design, safety profiles, and the engineering of more efficient delivery systems.
The largest share of the community's output is found in praseodymium research, accounting for 4.6% of all praseodymium studies, though this element represents only a small fraction of the community's total 3,310 papers. The community publishes most frequently in Human Gene Therapy and Molecular Therapy.
Recent work continues to focus on overcoming pre-existing immunity to AAV vectors, improving the safety of high-dose systemic administration, and expanding gene-editing applications to conditions like Huntington’s disease and hemophilia.